BUFFALO, NY – Five major research centers in New York have banded together to share resources and a manufacturing facility in ...

The firm is touting its AI-driven foundation model's ability to predict how any patient will respond to any drug, allowing sponsors to fine-tune their trials.

The firm will explore FORX-428's activity in patients whose tumors harbor DNA damage repair mutations or mutations that cause high DNA replication stress.

Kumquat, based in San Diego, received US Food and Drug Administration clearance of its investigational new drug application for the KRAS G12D inhibitor in July. The firm will be responsible for ...

In the EMPEROR trial, children with a confirmed variant in the SCN1A gene not associated with gain-of-function mutations will receive zorevunersen or a placebo.

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

Patients on a combination of toripalimab and RemeGen's anti-HER2 antibody disitamab vedotin fared better than those on a chemotherapy regimen.

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Fifteen percent of patients who received Skysona within clinical trials have since been diagnosed with hematologic malignancies.

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

During a Q2 earnings call, the firm discussed progress on an FGFR2b antibody, a subcutaneous version of Blincyto, and ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...